Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888312 | 0.83 | — | — | |
| SCHEMBL1456355 | 0.83 | — | — | |
| SCHEMBL6689441 | 0.79 | — | — | |
| SCHEMBL6365020 | 0.79 | — | — | |
| SCHEMBL4138289 | 0.79 | — | — | |
| SCHEMBL1706668 | 0.79 | — | — | |
| SCHEMBL9015336 | 0.76 | — | — | |
| SCHEMBL2051101 | 0.76 | — | — | |
| SCHEMBL9405105 | 0.76 | — | — | |
| SCHEMBL6971777 | 0.75 | HTR7 (0.30) | HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119486735-A | For the treatment of glomerular diseases | 载度思生命科学有限公司 | 2025-02-18 | — | — | CN | claimed |
| EP-2350181-B1 | ELECTRICALLY CONDUCTIVE COMPOSITE MATERIAL AND THERMOELECTRIC DEVICE COMPRISING THE MATERIAL | 3M INNOVATIVE PROPERTIES CO (US) | 2018-05-16 | — | — | EP | claimed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-20240417392-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2024-12-19 | — | — | US | disclosed |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-10-10 | — | — | US | disclosed |
| US-11713308-B2 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-08-01 | — | — | US | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230044255-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2023-02-09 | — | — | US | disclosed |
| US-11465989-B2 | Guanidine compounds and use thereof | ImmunoMet Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3707139-B1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | CENTRE NAT RECH SCIENT (FR) | 2022-02-16 | — | — | EP | disclosed |
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-23 | — | — | US | disclosed |
| WO-2003004603-A2 | METHODS OF MODULATING PHARMACOKINETICS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| EP-1256574-A1 | NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-6448443-B1 | GENERATED FROM DIVERSIFIABLE SCAFFOLDS SYNTHESIZED FROM THE PYRIDINE-BASED TEMPLATE ISONICOTINAMIDE; ALSO PROVIDES A NOVEL ORTHO-NITROBENZYL PHOTOLINKER; SYNTHESIZED FROM A SHIKIMIC ACID BASED EPOXYOL TEMPLATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-09-10 | — | — | US | disclosed |
| EP-1226146-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | ABBOTT LABORATORIES | 2002-04-25 | — | — | US | disclosed |
| WO-2002026697-A2 | AROMATIC DERIVATIVES WITH HIV INTEGRASE INHIBITORY PROPERTIES | PHARMACOR, INC. (CA) | 2002-04-04 | — | — | WO | disclosed |
| US-6306860-B1 | ANTIVIRAL ACTIVITIES AGAINST HEPATATIS B AS WELL AS HUMAN IMMUNODEFICIENCY VIRUS | DONG WHA PHARM. INC. CO., LTD. (KR) | 2001-10-23 | — | — | US | disclosed |
| WO-2001032655-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2001-05-10 | — | — | WO | disclosed |
| US-5109008-A | Analgesics, diuretics, antiischemic agents | GLAXO GROUP LIMITED (GB) | 1992-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230044255-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPA, VAPB, SLC10A1 | HTR7 3684/4885 |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, LIPC | HTR7 4107/4885 |
| US-11465989-B2 | Guanidine compounds and use thereof | PC, TFAM, PCK2 | HTR7 4502/4885 |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | NQO2, NQO1, NDUFA7 | HTR7 2710/4885 |
| US-20240417392-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPA, VAPB, SLC10A1 | HTR7 3684/4885 |
| US-11713308-B2 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | VAPA, VAPB, SLC10A1 | HTR7 3684/4885 |
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | BET1, BRD4, BRD3 | HTR7 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.